Free Trial

Abbott Laboratories (ABT) Stock Price, News & Analysis

Abbott Laboratories logo
$86.25 -0.92 (-1.05%)
Closing price 03:59 PM Eastern
Extended Trading
$86.62 +0.37 (+0.42%)
As of 06:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Abbott Laboratories Stock (NYSE:ABT)

Advanced

Key Stats

Today's Range
$86.15
$87.69
50-Day Range
$87.18
$116.21
52-Week Range
$86.15
$139.06
Volume
12.45 million shs
Average Volume
11.82 million shs
Market Capitalization
$150.23 billion
P/E Ratio
24.16
Dividend Yield
2.92%
Price Target
$119.43
Consensus Rating
Moderate Buy

Company Overview

Abbott Laboratories Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
100th Percentile Overall Score

ABT MarketRank™: 

Abbott Laboratories scored higher than 100% of companies evaluated by MarketBeat, and ranked 1st out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Abbott Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 2 strong buy ratings, 19 buy ratings, 5 hold ratings, and no sell ratings.

  • Upside Potential

    Abbott Laboratories has a consensus price target of $119.43, representing about 38.0% upside from its current price of $86.52.

  • Amount of Analyst Coverage

    Abbott Laboratories has been the subject of 23 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Abbott Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for Abbott Laboratories are expected to grow by 10.58% in the coming year, from $5.48 to $6.06 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Abbott Laboratories is 24.24, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.37.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Abbott Laboratories is 24.24, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.22.

  • Price to Earnings Growth Ratio

    Abbott Laboratories has a PEG Ratio of 1.46. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Abbott Laboratories has a P/B Ratio of 2.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Abbott Laboratories' valuation and earnings.
  • Percentage of Shares Shorted

    1.25% of the float of Abbott Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    Abbott Laboratories has a short interest ratio ("days to cover") of 2.26, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Abbott Laboratories has recently decreased by 8.73%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Abbott Laboratories pays a meaningful dividend of 2.88%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Abbott Laboratories has been increasing its dividend for 54 years.

  • Dividend Coverage

    The dividend payout ratio of Abbott Laboratories is 70.59%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Abbott Laboratories will have a dividend payout ratio of 41.58% next year. This indicates that Abbott Laboratories will be able to sustain or increase its dividend.

  • Read more about Abbott Laboratories' dividend.
  • News Sentiment

    Abbott Laboratories has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 33 news articles for Abbott Laboratories this week, compared to 14 articles on an average week.
  • Search Interest

    232 people have searched for ABT on MarketBeat in the last 30 days. This is an increase of 176% compared to the previous 30 days.
  • MarketBeat Follows

    65 people have added Abbott Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 829% compared to the previous 30 days.
  • Cluster Insider Buying

    2 insiders have purchased shares of Abbott Laboratories in the last three months. Multiple insiders buying is a strong bullish signal.

  • Insider Buying vs. Insider Selling

    In the past three months, Abbott Laboratories insiders have bought 219.40% more of their company's stock than they have sold. Specifically, they have bought $1,127,800.00 in company stock and sold $353,097.00 in company stock.

  • Percentage Held by Insiders

    0.46% of the stock of Abbott Laboratories is held by insiders.

  • Percentage Held by Institutions

    75.18% of the stock of Abbott Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Abbott Laboratories' insider trading history.
Receive ABT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abbott Laboratories and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABT Stock News Headlines

Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
AbbVie logo displayed above a medical vial and syringe on a laboratory surface.
AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead? (ABT)
AbbVie's early 2026 price pullback is an irresistable opportunity for buy-and-hold investors looking for income and compounding opportunities.
Abbott Laboratories logo displayed on a white wall inside a modern medical facility.
Abbott Stock Crash: Rebound Could Be Coming Fast
Abbott Laboratories' stock price sell-off is overextended in mid-April, creating an opportunity that income investors will not want to miss.
Laptop displaying Abbott logo in a clinic waiting room, highlighting healthcare company amid stock downturn context.
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?
Abbott Laboratories' recent stock price dip contrasts with its strong Medical Devices division, creating a noteworthy opportunity for dividend investors.
See More Headlines

ABT Stock Analysis - Frequently Asked Questions

Abbott Laboratories' stock was trading at $125.30 at the beginning of 2026. Since then, ABT stock has decreased by 31.0% and is now trading at $86.5170.

Abbott Laboratories (NYSE:ABT) announced its earnings results on Thursday, April, 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating the consensus estimate of $1.14 by $0.01. The business's revenue for the quarter was up 7.8% on a year-over-year basis.
Read the conference call transcript
.

Abbott Laboratories subsidiaries include these companies: Cephea Valve Technologies, Alere, St. Jude Medical, Kalila Medical, Tendyne Holdings Inc., Veropharm, Topera Inc., and more.

Top institutional shareholders of Abbott Laboratories include Bank of New York Mellon Corp (0.71%), Assenagon Asset Management S.A. (0.25%), Sumitomo Mitsui Trust Group Inc. (0.22%) and Principal Financial Group Inc. (0.20%). Insiders that own company stock include Daniel J Starks, Robert B Ford, Jr Robert E Funck, Jr Robert E Funck, Daniel Gesua Sive Salvadori, Mary K Moreland, Andrea F Wainer, Lisa D Earnhardt, Eric Shroff, Elizabeth C Cushman, John A Jr Mccoy and Philip P Boudreau.
View institutional ownership trends
.

Shares of ABT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Abbott Laboratories investors own include JPMorgan Chase & Co. (JPM), Chevron (CVX), NVIDIA (NVDA), Predictive Oncology (POAI), Bank of America (BAC), Meta Platforms (META) and AbbVie (ABBV).

Company Calendar

Record date for 2/13 Dividend
1/15/2026
Ex-Dividend for 2/13 Dividend
1/15/2026
Dividend Payable
2/13/2026
Record date for 5/15 Dividend
4/15/2026
Ex-Dividend for 5/15 Dividend
4/15/2026
Last Earnings
4/16/2026
Today
5/06/2026
Dividend Payable
5/15/2026
Next Earnings (Estimated)
7/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Health Care Equipment
Current Symbol
NYSE:ABT
CIK
1800
Employees
115,000
Year Founded
1888

Price Target and Rating

High Price Target
$143.00
Low Price Target
$92.00
Potential Upside/Downside
+38.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
26 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.57
Trailing P/E Ratio
24.16
Forward P/E Ratio
15.74
P/E Growth
1.46
Net Income
$6.52 billion
Net Margins
13.90%
Pretax Margin
18.03%
Return on Equity
17.62%
Return on Assets
10.01%

Debt

Debt-to-Equity Ratio
0.56
Current Ratio
1.39
Quick Ratio
1.01

Sales & Book Value

Annual Sales
$44.33 billion
Price / Sales
3.39
Cash Flow
$6.89 per share
Price / Cash Flow
12.52
Book Value
$30.26 per share
Price / Book
2.85

Miscellaneous

Outstanding Shares
1,741,810,000
Free Float
1,733,801,000
Market Cap
$150.23 billion
Optionable
Optionable
Beta
0.65

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NYSE:ABT) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners